Halozyme Therapeutics HALO All other foreign — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's all other foreign — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's all other foreign — total revenues?
- Halozyme Therapeutics (HALO) reported all other foreign — total revenues of $8.33M in Q4 2025.
- How has Halozyme Therapeutics's all other foreign — total revenues changed year-over-year?
- Halozyme Therapeutics's all other foreign — total revenues increased by 249.9% year-over-year, from $2.38M to $8.33M.
- What is the long-term trend for Halozyme Therapeutics's all other foreign — total revenues?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's all other foreign — total revenues has grown at a 70.2% compound annual growth rate (CAGR), from $3.97M to $33.33M.
- What does all other foreign — total revenues mean?
- Total revenue earned from all international markets that are not reported as separate, major geographic segments.
- How do you interpret all other foreign — total revenues?
- An increase suggests successful market penetration or expansion in secondary international territories, while a decrease may indicate market saturation, regulatory headwinds, or reduced licensing activity in those regions.
- How does all other foreign — total revenues compare across companies?
- Peers often report similar 'Rest of World' or 'Other International' revenue buckets, though the composition of these regions varies significantly based on the company's global footprint and distribution strategy.